Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.63 |
| ▸ | FLT4 | P35916 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | RARB | P10826 | 1/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | XBP1 | P17861 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL5143071 | 0.98 | EPHA2 (0.61) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL5143074 | 0.97 | EPHA2 (0.60) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL5316747 | 0.88 | KMT2A (0.66) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL6211205 | 0.87 | LMNA (0.50) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL8195587 | 0.86 | EPHA2 (0.48) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL13315750 | 0.86 | EPHA2 (0.63) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL9149681 | 0.86 | EPHA2 (0.57) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL7008249 | 0.86 | EPHA2 (0.48) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| SCHEMBL19971429 | 0.86 | KEAP1 (0.48) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL8209872 | 0.85 | EPHA2 (0.90) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6114531-A | Process for preparing quinolone and naphthyridone carboxylic acids | PFIZER INC. (US) | 2000-09-05 | — | — | US | claimed |
| EP-0775114-B1 | PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS | PROCTER & GAMBLE (US) | 2000-03-22 | — | — | EP | claimed |
| EP-0976749-A1 | Process for preparing quinolone and naphthyridone carboxylic acids | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| US-5703231-A | Process for making antimicrobial compounds | THE PROCTER & GAMBLE COMPANY (US) | 1997-12-30 | — | — | US | claimed |
| WO-1996004247-A1 | PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-15 | — | — | WO | claimed |
| EP-0331960-B1 | Process for the preparation of enantiomerically homogeneous aminopyrrolidinyl naphthyridine and quinolone carboxylic acids | ABBOTT LAB (US) | 1994-05-18 | — | — | EP | claimed |
| EP-0331960-A2 | Process for the preparation of enantiomerically homogeneous aminopyrrolidinyl naphthyridine and quinolone carboxylic acids | ABBOTT LABORATORIES (US) | 1989-09-13 | — | — | EP | claimed |
| US-4859776-A | (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation | ABBOTT LABORATORIES (US) | 1989-08-22 | — | — | US | claimed |
| CN-110551124-B | Quinolone compound or agriculturally and pharmaceutically acceptable salt thereof, and preparation method and application thereof | 山东省联合农药工业有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-110551124-A | quinolone compound or agriculturally and pharmaceutically acceptable salt thereof, and preparation method and application thereof | SHANDONG UNITED PESTICIDE IND CO LTD | 2019-12-10 | — | — | CN | disclosed |
| EP-1861401-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-18 | — | — | EP | disclosed |
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | VYMED CORPORATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | VYMED CORPORATION (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| EP-0360258-A2 | Amino acid quinoline and naphthyridine derivatives | ABBOTT LABORATORIES (US) | 1990-03-28 | — | — | EP | disclosed |
| EP-0331960-A2 | Process for the preparation of enantiomerically homogeneous aminopyrrolidinyl naphthyridine and quinolone carboxylic acids | ABBOTT LABORATORIES (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4859776-A | (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation | ABBOTT LABORATORIES (US) | 1989-08-22 | — | — | US | disclosed |
| US-4851535-A | 2-(5-FLUORONICOTINOYL)ACETIC ACID DERIVATIVES, ANTIBACTERIAL 1-ARYL-1,4-DIHYDRO-4-OXONAPHTHYRIDINES | TOYAMA CHEMICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0302372-A1 | Naphthyridine antianaerobic compounds | ABBOTT LABORATORIES (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4704459-A | VILSMEIER REAGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | GDA, GMPS, GANC | EPHA2 4871/4885FLT4 4218/4885GSK3B 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.